Figure 2.

Fraction of patients experiencing no flares of inflammatory symptoms. Panel a shows a single trial simulation for 150 mg canakinumab, where 2 × 18 patients were treated from time zero, then randomized 1:1 to placebo at 56 days (red) or continued treatment (black). Panel b shows the simulation repeated 100 times.